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Protein carbonylsOxidative phosphorylation disorders are often associated with increased oxidative stress and antioxidant
therapy is frequently given as treatment. However, the role of oxidative stress in oxidative phosphorylation
disorders or patients is far from clear and consequently the preventive or therapeutic effect of antioxidants is
highly anecdotic. Therefore, we performed a systematic study of a panel of oxidative stress parameters (re-
active oxygen species levels, damage and defense) in ﬁbroblasts of twelve well-characterized oxidative phos-
phorylation patients with a defect in the POLG1 gene, in the mitochondrial DNA-encoded tRNA-Leu gene
(m.3243A>G or m.3302A>G) and in one of the mitochondrial DNA-encoded NADH dehydrogenase complex
I (CI) subunits. All except two cell lines (one POLG1 and one tRNA-Leu) showed increased reactive oxygen
species levels compared with controls, but only four (two CI and two tRNA-Leu) cell lines provided evidence
for increased oxidative protein damage. The absence of a correlation between reactive oxygen species levels
and oxidative protein damage implies differences in damage prevention or correction. This was investigated
by gene expression studies, which showed adaptive and compensating changes involving antioxidants and
the unfolded protein response, especially in the POLG1 group. This study indicated that patients display indi-
vidual responses and that detailed analysis of ﬁbroblasts enables the identiﬁcation of patients that potentially
beneﬁt from antioxidant therapy. Furthermore, the ﬁbroblast model can also be used to search for and test
novel, more speciﬁc antioxidants or explore ways to stimulate compensatory mechanisms.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Oxidative phosphorylation (OXPHOS) disorders are the most com-
mon group of inherited metabolic disorders characterized by a prima-
ry dysfunction of the OXPHOS system. The clinical and biochemical
heterogeneity of OXPHOS disorders is partly due to the dual (mito-
chondrial and nuclear DNA) genetic control of mitochondrial energy
production. Other factors that could explain this heterogeneity are
only partly resolved, awaiting further insight in the pathophysiologi-
cal processes. Recently, a number of papers have addressed the issueand Cell Biology, Maastricht
he Netherlands. Tel.: +31
l (H.J.M. Smeets).
rights reserved.of oxidative stress in OXPHOS disorders (e.g. [1–8]). The electron
transport chain in themitochondria is considered themajor source of re-
active oxygen species (ROS), which are by-products of the redox reac-
tions necessary to reduce NADH to NAD+ [9]. At low levels, ROS
behave as signaling molecules [10], but increased levels are damaging
for DNA, proteins and lipids as well as detrimental for cellular function
[11–14]. Therefore, cells are well equipped with antioxidant systems to
control ROS levels. Oxidative stress occurs when the balance between
pro-oxidants (ROS) and antioxidants is disturbed and antioxidants are
no longer able to maintain normal physiological ROS levels.
Increased ROS production has been described in patientswith clinical-
ly, biochemically [4,15,16] and/or genetically [17–19] diagnosed OXPHOS
disorders, in cybrid models [6,8] and in cell lines where the respiratory
chain was inhibited by chemicals [20]. The antioxidant status of tis-
sues or cell cultures from OXPHOS patients [1,5,6,16,19,21] was
1972 A.M. Voets et al. / Biochimica et Biophysica Acta 1817 (2012) 1971–1978investigated with variable and sometimes contradictory results.
Only few studies report the total picture of oxidative stress in
these patients, including ROS production, antioxidant defense and
the eventual oxidative damage [6,19,22]. The goal of this study
was to investigate the role of oxidative stress in three different ge-
netically characterized OXPHOS disorders: patients with mutations
in the POLG1 gene, patients with a tRNA leucine (tRNA-Leu) muta-
tion in the mtDNA (m.3243A>G and m.3302A>G) causing mitochon-
drial encephalomyopathy, lactic acidosis and stroke-like episodes
(MELAS) and patients with a mutation in one of the mtDNA encoded
complex I subunits. Complex I deﬁciency and tRNA-Leu mutations have
been associated with increased oxidative stress previously [19,23], al-
though not all studies could conﬁrm this [24]. Importantly, different pa-
rameters have been characterized to determine oxidative stress,
including increased probe oxidation [23] combinedwith antioxidant ex-
pression [24] and increased oxidative damage, or combinations of the
three [19]. For POLG1 mutations, a couple of studies were performed in
transgenic mice, but again with conﬂicting conclusions: transgenic
mouse models carrying the D257A mutation in the exonuclease domain
of polγdid not increase oxidative stress [25,26]whereas transgenicmice
with cardiac-targeted human mutant Y955C pol γ, affecting the poly-
merase domain, did [27].
Our study aimed at investigating parameters including ROS levels,
ROS detoxiﬁcation (glutathione levels, antioxidant gene expression)
and oxidative damage (protein carbonyls) in patient-derived ﬁbro-
blasts as a model system. Because the genetic defect might not stress
the cells to such an extent that relevant disease-associated changes
can be picked up, ﬁbroblasts were deprived of glucose to stimulate
energy production through oxidative phosphorylation. The changes
due to the genetic defect were corrected for the different culture con-
ditions. The suitability of this model has been demonstrated before
[24,28]. This patient-derived model will help to resolve the individu-
al, underlying adaptive mechanisms in each patient, thereby identify-
ing the subgroup of patients that will most likely beneﬁt from
antioxidant treatments or will be able to test the efﬁcacy of new
targeted candidate antioxidants.
2. Materials and methods
2.1. Patient ﬁbroblast cell lines
Fibroblasts were derived from skin biopsies of ﬁve patients with a
POLG1 mutation, four with a tRNA-Leu (m.3243A>G or m.3302A>G)
MELAS mutation, three with a mutation in an mtDNA encoded complexTable 1
Patient characteristics for primary ﬁbroblast cell lines.
Cell line Sex Age at biopsy (years) Passage number Grou
2862S F 24 18 POLG
06E0703 F 16 18 POLG
00E0741 F b1 18 POLG
3591 M 8 19 POLG
05E0536 F 1 19 POLG
2400 M 27 15 tRNA
1933 M 27 11 tRNA
2830 F 19 8 tRNA
1330 M 34 12 tRNA
3765 M 5 10 CI
2181 M 3 14 CI
1682 F 4 8 CI
C0388 19 Cont
C0407 19 Cont
C2244 14 Cont
a Patient cell lines are grouped according to their genetic defect: polymerase gamma m
mtDNA complex I subunit mutation (CI).
b Mutations are given at the protein level for POLG and at the mtDNA level for MELAS an
c The activities of the different OXPHOS complexes are expressed as the percentage of a
complex II, CIII = complex III, CIV = complex IV. n.a. = not applicable.I subunit, and three controls (Table 1). Fibroblastswere routinely cultured
in Dulbecco's modiﬁed Eagle medium (DMEM; Gibco, Paisley, UK)
supplemented with 10% fetal bovine serum, 0.2 mM uridine (Acros,
Geel, BE), penicillin and streptomycin. To stimulate energy production
by oxidative phosphorylation, ﬁbroblasts were cultured for 72 h without
glucose in the presence of galactose. Galactose medium consisted of
DMEM without glucose supplemented with 5.5 mM galactose (Sigma,
Zwijndrecht, Netherlands), 20% FBS, 0.2 mMuridine, penicillin and strep-
tomycin [29]. Measurementswere performed in primary cell cultures be-
tween passage 7 and 20. Except for the quantiﬁcation of reactive oxygen
species, cultures from the same cell line and condition were pooled and
the cell pellet was divided for the different assays.
2.2. Quantiﬁcation of reactive oxygen species
Reactive oxygen species (ROS) levels were measured as described
previously [23]. In short, ﬁbroblasts were incubated in HEPES–Tris me-
dium (132 mM NaCl, 4.2 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 10 mM
HEPES and 5.5 mM D-glucose or galactose, pH 7.4), containing 10 μM
hydroethidine (HEt; Molecular Probes, Paisley, UK) for 10 min at
37 °C. The reaction was stopped by thorough washing of the cells with
PBS. Culture dishes were mounted in an incubation chamber placed
on the stage of an inverted microscope (Axiovert 200 M, Carl Zeiss,
Jena, DE) equipped with a Zeiss 40×/1.3 NA ﬂuor objective. The cells
were excited at 490 nm using a monochromator (Polychrome IV, TILL
Photonics, Gräfelﬁng, DE). Fluorescence emission light was directed by
a 525DRLP dichroic mirror ﬁlter (Omega) onto a CoolSNAP HQ mono-
chrome CCD-camera (Roper Scientiﬁc, Vianen, NL) with an acquisition
time of 100 ms. Hardware was controlled with Metaﬂuor 6.0 software
(Universal Imaging Corporation, Downingtown, PA, USA). Processing
and analysis of ﬂuorescence images was performed with MetaMorph
6.1 (Universal Imaging Corporation). All cell lines were examined on
at least two and if possible up to four different days. In total, at least
150 cells (range 156–568) were analyzed on each day for each cell
line and condition.
2.3. Preparation of lysates for glutathione measurements and protein
carbonyls
Cell pellets were resuspended in ice-cold extraction buffer (0.1%
Triton X-100 and 0.6% sulfosalicylic acid in 0.1 M potassium phos-
phate buffer with 5 mM EDTA disodium salt, pH 7.5) and homoge-
nized with a Teﬂon pestle. After sonication and 2 freeze-thaw
cycles, the suspension was centrifuged for 4 min at 3000 g (4°) andpa Mutation(s)b OXPHOS complex activity c
p.467A>T HOM CI 67, CII 125, CIII 108, CIV 87, CS 93
p.467A>T HOM CI 54, CII 141, CIII 79, CIV 84, CS 71
p.227R>P+p.467A>T CI 34, CII 76,CIII 31, CIV 50, CS 227
p.305S>R+p.467A>T CI 50, CII 86, CIII 57, CIV 89, CS 142
p.467A>T+p.957A>P CI 63, CII 81, CIV 57, CS 150
-Leu m.3243A>G (80%) CI 43, CII 86, CIII 67, CIV 80, CS 125
-Leu m.3243A>G (90%) CI 50, CII 84, CIII 60, CIV 79, CS 117
-Leu m.3243A>G (83%) CI 57, CII 86, CIII 77, CIV 60, CS 100
-Leu m.3302A>G (50%) CI 62, CII 100, CIII 79, CIV 83, CS 108
ND1, m.3890G>A (80%) CI 34, CII 69, CIII 72, CIV 114, CS 160
ND5, m.13042G>A (86%) CI 50, CII 90, CIII 59, CIV 70, CS 110
ND5, m.13511A>T (60%) CI 52, CII 94, CIII 91, CIV 115, CS 105
rol – n.a.
rol – n.a.
rol – n.a.
utations (POLG), mtDNA tRNA leucine mutation with MELAS phenotype (MELAS) and
d CI, the mutation percentage of the mtDNA mutations is given between ( ).
control population, normalized to citrate synthase (CS) activity. CI = complex I, CII =
1973A.M. Voets et al. / Biochimica et Biophysica Acta 1817 (2012) 1971–1978the supernatant was stored at−70° until further use. Protein concen-
trations were determined using the Bio-Rad Protein Assay.
2.4. Glutathione measurement
Reduced (GSH) and oxidized (GSSG) glutathione were measured
in the cell lysates as described in [30].
2.5. Protein carbonyl detection
To detect oxidative modiﬁcations of proteins, the Oxyblot™ Pro-
tein Oxidation Detection kit (Millipore, Amsterdam, NL) was used.
After derivatization of the carbonyl groups in the cell lysates with
di-nitrophenylhydrazone, oxidatively modiﬁed proteins were detected
by immunoblotting according to the manufacturer's protocol in two
replicates. Results were normalized to beta-actin protein levels in dif-
ferent lanes of the same gels.
2.6. Oxidative stress related gene expression
The expression levels of genes involved in oxidative stress and in-
ﬂammation were measured using the OxyGenes™ microarrays
(Probiox SA, Liege, BE) [31]. RNA was isolated from cell pellets with
the High Pure RNA Isolation kit (Roche, Woerden, NL). RNA quantity
and purity were determined spectrophotometrically using the
Nanodrop ND-1000 (Nanodrop Technologies, Wilmington, DE, USA)
and RNA integrity was assessed by determining the RNA 28S/18S
ratio using the Bioanalyser 2100 (Agilent Technologies, Santa Clara,
CA, USA). 2 μg of RNA was reverse transcribed into cDNA according
to the 3DNA Array 900 protocol (Genisphere, Hatﬁeld, PA, USA).
Next, cDNA was hybridized on the OxyGenes™ slides overnight,
followed by washing steps and hybridization of Cy™ 3-labeled
3DNA capture reagent according to the manufacturer's procedures
(Genisphere). To assess the raw probe signal intensities, slides were
scanned using the LS Reloaded laser scanner (Tecan, Männedorf,
CH) with gain settings 160, 180 and 200 and analyzed using
Array-Pro analyzer software (MediaCybernetics, Bethesda, USA) or
scanned using the Agilent High-Resolution Microarray Scanner (Agilent
Technologies, Amstelveen, NL) and analyzed using Feature Extraction
10.7 software (Agilent Technologies).
2.7. Data analysis
The data were analyzed using multivariate Gaussian linear regres-
sion including a one (protein carbonyls and Oxygenes™) or two level
(ROS levels) random effect to take into account the dependence
among observations from the same subject (all) and the dependence
among the different measurement days (ROS levels). For the ROS level
analysis, the medium (glucose and galactose) and the group (control,
complex I, tRNA-Leu and POLG) were included during the analysis as
well as interactions among these when required. For the protein car-
bonyl analysis, the reference protein (beta-actin), concentration, day,
gel number, medium and group were included. The inference criterion
used for comparing the models is their ability to predict the observed
data, i.e. models are compared directly through their minimized minus
log-likelihood. When the numbers of parameters in models differ, they
are penalized by adding the number of estimated parameters, a form of
the Akaike information criterion (AIC) [32]. First, all cell lines were ana-
lyzed together in the patient groups indicated and, next, each cell line
was also investigated separately. In each case, the relevant group differ-
ences were reported if the model with the smallest AIC contained any
combination of one or more groups. For the Oxygenes™ analysis, one
of the 30 housekeeping genes, the pooled sample, the background inten-
sity, the scanner used, the medium and group were included during the
analysis as well as interactions among these when required. Similarly to
the ROS and protein carbonyl analysis, the AIC was used to assesswhether there was a group effect. First, each gene was analyzed for all
cell lines in the patient groups together and then the analysiswas also re-
peated for all genes but considering each cell line separately. In each
analysis, the relevant group differences were reported if the model
with the smallest AIC contained any combination of one ormore groups.
Importantly, the reported fold changes are estimated values by the
models, taking into account both the effect of the mutation and the me-
dium.Glutathione datawas analyzedusing the univariate analysis of var-
iance in the SPSS software package.
3. Results
3.1. Increased ROS levels in most of the patient cell lines
ROS levels, quantiﬁed by the oxidation rate of hydroethidine (HEt),
were assessed in the control and patient cell lines under glucose and ga-
lactose conditions (Table 2). Unlike the fold changes for the patient
groups, analysis of individual cell lines and controls did not always esti-
mate amedium effect, i.e. a different fold change for the glucose and ga-
lactose condition, due to low power. In these cases, the fold changes
represent the difference between the speciﬁc patient and control ﬁbro-
blasts regardless of the medium. Except for two cell lines, one POLG1
mutant (06E0703; p.467A>T homozygote) and one tRNA-Leu mutant
(1330; m.3302A>G), all other cell lines showed increased HEt oxida-
tion compared with control cell lines in glucose and galactose medium.
HEt oxidation was highest in the CI group, although one of the POLG1
cell lines (05E0536; p.467A>T+p.957A>P) presented with the
highest HEt oxidation rate. Although the main focus was on changes
due to themutation and not the differences between culture conditions,
six cell lines showed a larger fold change for HEt oxidation (versus con-
trols) in galactose compared with glucose. Galactose medium also in-
duced a 1.53 fold increase in HEt oxidation in controls (Table 2).
Furthermore, an aliquot with a different passage number of cell lines
C0388, 2181 and 1682 was thawed at a different time point to check
the assay reproducibility. The same results were obtained (results not
shown).
3.2. Oxidative damage
The levels of protein carbonyls, an index for oxidative protein dam-
age, were signiﬁcantly elevated in three patient cell lines cultured with
glucose and galactose: tRNA-Leu cell lines 2400 (80%m.3243A>G) and
1933 (90%m.3243A>G) and CI cell line 3765 (80%m.3890G>A). CI cell
line 1682 (60% m.13511A>T) only showed increased levels of protein
carbonyls compared with controls when cultured with galactose medi-
um (Table 3).
3.3. Stress-related gene expression and antioxidant defense
To examine ROS-related gene expression changes, the transcrip-
tion levels of stress-related genes were determined using OxyGenes
™microarrays. Of the 165 genes on the microarray, 38 genes showed
more than 20% difference in expression above the background level in
at least one of the groups and one of the culture media. Of these 38
genes, 10 were altered due to the genetic defect only, as their expres-
sion was not inﬂuenced by the culture medium in controls and pa-
tients (Table 4). Therefore these were considered speciﬁc for the
genetic defects and included, amongst others, heat shock protein
(HSPA1A), oxidative stress related (SOD1, PON2 [33,34], MT1M
[35,36]) and inﬂammatory (ICAM1, IL2RG, TNFRSF1B) genes. The ex-
pression of the remaining 28 genes was altered due to both the culture
medium and genetic defect (Supplementary Table 1). The POLG group
showed the highest number of differentially expressed genes com-
pared with controls, both in glucose and galactose medium. The galac-
tose medium induced larger expression differences compared to
controls of 17 stress-related genes in the POLG group (Supplementary
Table 3
Statistical analysis of oxidative protein damage (protein carbonyls).
Cell line Glucose mean (C.I.) Galactose mean (C.I.)
Comparing patient groups
Control (3 cell lines) 1.00
POLG (5 cell lines) 1.07 (0.94–1.21)
tRNA-Leu (4 cell lines) 1.30 (1.13–1.48)
CI (3 cell lines) 1.22 (1.06–1.41)
Comparing cell lines
POLG
2862S 1.07 (0.76–1.50)
06E0703 0.93 (0.81–1.08)
00E0741 1.14 (0.96–1.35)
3591 1.15 (0.92–1.43)
05E0536 0.92 (0.73–1.66)
tRNA-Leu
2400 1.25 (1.06–1.47)
1933 1.56 (1.29–1.89)
2830 1.26 (0.90–1.77)
1330 1.14 (0.94–1.39)
CI
3765 1.36 (1.07–1.74)
2181 1.08 (0.96–1.22)
1682 1.12 (0.76–1.65) 2.22 (1.79–2.75)
Protein carbonyls as measured using the Oxyblot assay, expressed as fold change
compared with control in the respective culture medium. Values are estimated fold
changes for patients versus controls provided by the model, taking into account both
the effect of the mutation and the medium. Values for the patient groups and the
individual cell lines were estimated in separate analyses. If the fold change was not
signiﬁcantly different for a cell line or group between both media (due to less power
compared with the analysis of the groups), the fold change of the best ﬁtting model
was estimated for glucose and galactose together. Values in bold differ signiﬁcantly
from control.
1974 A.M. Voets et al. / Biochimica et Biophysica Acta 1817 (2012) 1971–1978Table 1). In contrast, the tRNA-Leu and CI groups showed less differen-
tially expressed genes, both in glucose and galactose (Supplementary
Table 1). A closer examination of the gene expression changes of classi-
cal antioxidant genes in the individual cell lines (Table 5) revealed an
inconsistent picture. On the one hand, genes could behave comparable
in multiple cell lines of one or more patient groups in one or both cul-
ture conditions (e.g. GSR in POLG glucose and galactose, GPX1 in
tRNA-Leu galactose, SOD1 in tRNA-Leu and CI galactose). Whereas, on
the other hand, their expression changed differently, either up or
down, in cell lines of the same group in one or both culture conditions
(e.g. GPX1 in POLG glucose and galactose, SOD1 in tRNA-Leu and CI glu-
cose) (Table 5).
Reduced (GSH) and oxidized (GSSG) glutathione levels were mea-
sured to evaluate the oxidative status of the cell lines as indicated by
their ratio (Fig. 1). Univariate analysis of variance did not detect any
signiﬁcant difference between the groups or culture conditions. As
can be appreciated from Fig. 1, there was a large variation between
cell lines of patients within one group, indicating patient-speciﬁc ef-
fects. Three patient cell lines (tRNA-Leu 1933, CI 3765 and CI 2181)
showed a GSH/GSSG ratio below the control range in the glucose sit-
uation, indicating a more oxidized state. In addition, in galactose me-
dium all tRNA-Leu cell lines and CI cell line 3765 were in a more
oxidized state (lower GSH/GSSG ratio) than the control range
(Fig. 1). POLG1 cell lines seemed to be in a more reduced state than
controls, especially in the galactose condition.
3.4. Correlations between different parameters
To investigate correlations between the different parameters (ROS
levels, oxidative protein damage, GSH/GSSG ratio and classic antioxi-
dant gene expression) and between these parameters and sex and
age, a correlation matrix was created (Table 6). Statistical signiﬁcant
correlations (p valueb0.05) were only detected between ROS levels
and CAT expression fold changes (Pearson's r −0.508) and protein
carbonyl levels and GPX1 expression fold changes (Pearson's r 0.454).Table 2
Statistical analysis of ROS levels as measured by HEt oxidation.
Cell line Glucose mean (C.I.) Galactose mean (C.I.)
Comparing patient groups
Control (3 cell lines) 1.00 1.53 (1.49–1.57)a
POLG 1.47 (1.12–1.82) 1.71 (1.34–2.18)
tRNA-Leu 1.48 (1.14–1.83) 1.72 (1.35–2.19)
CI 1.87 (1.47–2.27) 2.28 (1.73–3.01)
Comparing cell lines
POLG
2862S 1.36 (1.14–1.63) 1.96 (1.65–2.34)
06E0703 1.12 (0.96–1.30)
00E0741 1.18 (1.04–1.33)
3591 1.51 (1.35–1.70)
05E0536 2.51 (2.13–2.95) 4.80 (4.08–5.65)
tRNA-Leu
2400 1.45 (1.28–1.64)
1933 1.30 (1.12–1.51) 1.92 (1.65–2.23)
2830 1.74 (1.46–2.08) 2.52 (2.10–3.03)
1330 1.10 (0.96–1.25)
CI
3765 1.61 (1.37–1.90) 2.38 (2.01–2.83)
2181 2.31 (1.98–2.69)
1682 1.36 (1.20–1.54)
HEt oxidation expressed as fold change compared with control in the respective
culture medium. Values are estimated fold changes for patients versus controls
provided by the model, taking into account both the effect of the mutation and the
medium. Values for the patient groups and the individual cell lines were estimated in
separate analyses. If the fold change was not signiﬁcantly different for a cell line
between both media, the fold change of the best ﬁtting model was estimated for
glucose and galactose together. Values in bold differ signiﬁcantly from control in the
respective medium or glucose and galactose together.
a Versus control glucose, only applies for the patient groups comparison.4. Discussion
The goal of this study was to characterize different oxidative stress
parameters in three groups of patients with a genetically characterized
mitochondrial disorder caused bymutations either in the POLG1 gene orTable 4
Statistical analysis of stress-related gene expression changes due to disease without
medium effect.
Gene FC CI vs
control
FC POLG vs
control
FC tRNA-Leu vs
control
FC All vs
control
HSPA1A 3.39
(2.80–4.09)
ICAM1 1.58
(1.33–1.87)
IGFBP3 1.40
(1.35–1.45)
IL2RG 0.68
(0.56–0.82)
1.27
(1.03–1.56)
0.68 (0.56–0.82)
MT1M 2.36
(2.07–2.69)
PON2 0.58
(0.38–0.89)
SIRT1 2.60
(1.36–4.96)
SOD1 1.99
(1.71–2.31)
SOS2 1.38
(1.27–1.50)
TNFRSF1B 0.67
(0.59–0.76)
Fold changes of stress-related genes in patients versus controls as measured by the
OxyGenes™microarrays. Fold changes were the same for glucose and galactose medi-
um. Values are estimated fold changes for patient groups versus controls provided by
the model, taking into account both the effect of the mutation and the medium. If
the fold change was not signiﬁcantly different for all patient groups, the fold change
of the best ﬁtting model was estimated for three groups together and provided in the
‘All vs control’ column. Only signiﬁcant results are shown. 95% conﬁdence intervals
for the fold changes are shown between brackets.
Table 5
Statistical analysis of antioxidant gene expression for each cell line.
Gene CAT SOD1 GSR GPX1
Cell line Glu Gal Glu Gal Glu Gal Glu Gal
POLG
2862S 1.37 2.35 19.05 2.42 0.77 2.50
06E0703 1.36 1.21
00E0741 1.29 1.22 1.51 0.58
3591 1.46
05E0536 0.73
tRNA-Leu
2400 14.35 0.64 1.75 0.54
1933 0.67
2830 0.56 2.64 0.42
1330 0.75 0.51
CI
3765 1.40
2181 4.11 0.54 1.17 0.79
1682 0.61 1.29
Fold changes are given relative to the average control (glucose or galactose). Values are
estimated fold changes for patients versus controls provided by the model, taking into
account both the effect of the mutation and the medium. If the fold change was not
signiﬁcantly different for a cell line between both media, the fold change of the best
ﬁtting model was estimated for glucose and galactose together. Blank cells indicate
no (b10% change) or a non-signiﬁcant difference compared with controls.
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Fig. 1. Ratio of reduced (GSH) to oxidized (GSSG) glutathione levels for each patient
group and individual cell line cultured in glucose and galactose.
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predominantly use glycolysis for energy production when cultured
with high glucose availability [24,37,38]. Hence, cell lines were forced
to derive ATP from OXPHOS using glucose-free galactose medium
[39]. An overview of the results is shown in Table 7.
4.1. Increased ROS levels in the majority of primary ﬁbroblasts of
OXPHOS patients
ROS levels were increased in most patient-derived cell lines, both
when cultured with glucose and galactose medium (Table 7). The
moderate increase in ROS levels in control ﬁbroblasts due to the re-
placement of glucose by galactose might reﬂect increased basal
OXPHOS-related ROS production due to the switch from glycolysis
to OXPHOS for energy production and the somewhat more oxidized
cellular redox state (2/3 control cell lines, Fig. 1). Our results indicat-
ed that ROS levels could already be increased by quite moderate
OXPHOS deﬁciencies (e.g. CI activity lower than 70% of the average
control activity), as shown for most ﬁbroblasts in this study and pre-
viously [23]. The authors have shown before using the same protocol
that HEt oxidation occurs with inhibition of complex I and III but not
complex V [23,40] and that similar results can be obtained with the
MitoSOx Red and CM-H2DCF probes [41]. A drawback is that method
cannot distinguish the exact site(s) of HEt oxidation and that the
exact mechanism therefore remains speculative [23]. HEt is oxidized
by superoxide and non-superoxide free radicals, yielding two differ-
ent products [42] which are difﬁcult to distinguish using ﬂuorescence
microscopy [43,44]. Therefore, we consider the results as ‘ROS levels’
instead of superoxide. Other proteins that might inﬂuence the mea-
sured ROS levels are alpha-ketoglutarate dehydrogenase in the tricar-
boxylic acid cycle [45,46] and NADPH oxidases (NOX) [47], all
suggested to be inﬂuenced by the redox status of cells [48]. Therefore,
genetically deﬁned OXPHOS deﬁciencies might not only increase ROS
levels by electron leakage at the OXPHOS complexes but also by alter-
ing the NAD+/NADH ratio.
4.2. Adaptive processes in ﬁbroblasts of OXPHOS patients
Most cell lines showed increased ROS levels but no increased oxida-
tive protein damage. Stress-induced adaptive gene expression changes,especially in the POLG1 cell lines, might account for these ﬁndings. The
existence of such a delicate balance is supported by the presence of ox-
idative damage in one CI mutant ﬁbroblast cell line in galactose but not
glucose medium, associated with higher ROS levels. The increased ex-
pression of stress-inducible HSPA1A, DNAJB1 and HSF2 in the glucose
and/or galactose condition in patient cell lines pointed to a stress con-
dition induced by the genetic defect. The induction of these genes indi-
cates activation of the unfolded protein response to prevent or repair
oxidative damage. However, repair processes are highly energy de-
manding. Therefore, probably also the remaining energy capacity of a
defect OXPHOS system plays a role in the faith of cells. Recently, train-
ing has been shown to be beneﬁcial for improving oxidative metabo-
lism in muscle [49] and to induce antioxidant-related adaptations,
enhancing the ability to cope with oxidative stress [50]. Thus, possibly
also the physical activity or training of patients plays a role in howwell
their antioxidant systems will be able to cope with or adapt to the in-
creased ROS levels caused by their genetic defect. The main speciﬁc re-
sults for each patient group are being discussed here in more detail.4.2.1. Patients with mutations in mtDNA encoded complex I subunits
The complex I group presented the highest ROS levels, accompanied
with most oxidative protein damage (2/3 cell lines) and only few
changes in antioxidant gene expression (Table 7). Interestingly, the CI
cell line with the highest ROS levels was the cell line without oxidative
damage, indicating sufﬁcient adaptation to or compensation of the de-
fect which was insufﬁcient in the other two cell lines. Increased ROS
levels have been detected previously in cells or tissues of patients
with a genetically (nuclear [23] or mitochondrial DNA [16]) and/or
functionally [4] characterized CI deﬁciency. The ﬁnding is not surprising
as CI is one of the major ROS sources in mitochondria [51,52]. Luo et al.
observed increased lipid peroxidation in ﬁbroblasts of patients with CI
deﬁciency [53], but this was not detected in another study by Verkaart
et al. [15]. The only publication reporting on oxidative protein damage
in CI deﬁciency involved cybrids carrying the 3460, 11778 and 14484
Leber mutations showing increased protein carbonylation [54]. This
nicely supports our results. In contrast to the lymphoblast cell lines
frombiochemically characterized CI deﬁcient patientswith predominant-
ly (5/6 cell lines) homoplasmic mtDNAmutations [16], we did not detect
consistently increased expression of SOD, CAT,GPX andGST in our patients
with a genetic defect inmtDNA CI genes [16]. However, in their study, in-
creased expression of the genes in the presence of elevated ROS levels
was not correlated with increased expression of the corresponding pro-
teins and they actually measured lower antioxidant activity of these en-
zymes, except for SOD1. Nevertheless, they concluded, mainly based on
Table 6
Correlation matrix.
ROS levels Protein carbonyl level GSH/GSSG ratio CAT expression FC SOD1 expression FC GSR expression FC
ROS levels
Protein carbonyl level −0.158
GSH/GSSG ratio 0.076 0.334
CAT expression FC −0.508 −0.197 −0.101
SOD1 expression FC −0.001 −0.050 0.020 0.227
GSR expression FC 0.258 −0.170 −0.197 −0.160 0.400
GPX1 expression FC 0.225 0.454 0.401 −0.177 0.327 0.234
Correlation matrix for ROS levels, protein carbonyl levels, the GSH/GSSG ratio and fold changes of classic antioxidant genes. The Pearson correlation values produced by SPSS are
shown; signiﬁcant correlations are depicted in bold (pb0.05).
1976 A.M. Voets et al. / Biochimica et Biophysica Acta 1817 (2012) 1971–1978the enzyme data, that ROS levels and alteration of ROS scavenging en-
zymeswere good parameters to assign antioxidant therapy, evenwithout
measuring oxidative damage parameters. The absence of antioxidant en-
zyme activitymeasurements is a limitation of our study, however, the ox-
idative damage parameter, which we did examine, is a more appropriate
biomarker to estimate the eventual consequences of increased ROS levels
in ﬁbroblasts. Antioxidant markers are more a measure of endogenous
protection and not of damage.
4.2.2. Patients with mutations in tRNA leucine genes
All three cell lines with the m.3243A>G mutation (80–90%
heteroplasmy) experienced increased ROS levels, whereas the cell line
with the m.3302A>G mutation (60%) did not (Table 7). In this study
with primary patient ﬁbroblast cell lines, the lack of increased ROS levelsTable 7
Summarizing overview of oxidative stress parameters for each cell line.
*based on the combination of ROS levels, oxidative damage and antioxidant gene expression
red = negative (increased ROS, increased damage, insufﬁcient defense) change comparedin them.3302A>Gcell line is likely due to the lowermutationpercentage
but a different molecular mechanism compared with the m. 3243A>G
tRNA-Leu mutation cannot be excluded [55]. The m.3302A>G and
m.3243A>G tRNA-Leumutations have been shown to increase superox-
ide production in homoplasmic cybrid models with deﬁciencies of
OXPHOS complexes I, III, IV and V [56], whereas in our group complex I
deﬁciency was most prominent, and in muscle of patients with the
m.3243A>G mutation [19]. Oxidative protein damage was observed in
twom.3243A>G cell lines. Again, the cell linewith the highest ROS levels
did not show oxidative damage in galactose. For the tRNA-Leu patients,
only few studies previously reported on oxidative damage. One study
detected increased protein carbonylation in muscle biopsies [19] while
two other studies did not observe increased oxidative damage in cybrids
carrying the homoplasmic 3243A>G [6,55] or 3302A>G [55] mutations.in ﬁbroblasts. Cell color code: yellow = no signiﬁcant change compared with control,
with control, green = positive (antioxidant response) change compared with control.
1977A.M. Voets et al. / Biochimica et Biophysica Acta 1817 (2012) 1971–1978There have been no reports on oxidative stress/damage in mutant
tRNA-Leu ﬁbroblasts so far.
Our results differ partly from previous studies on antioxidant en-
zymes in MELAS patients, reporting increased gene expression and
activities of SOD, CAT and GPX, although studies are difﬁcult to com-
pare due to differences in cell types, mutation load and analytical ap-
proaches [5,6,57]. In one study, the mutation load was considerably
lower (b45% heteroplasmy) than in our ﬁbroblasts and myoblast cul-
tures were used [5] and ROS levels, were not determined in these
myoblast cultures. Therefore, it is not certain that the gene expression
changes resulted from increased ROS production related to the
mtDNA mutations. A second study did not quantify their immunohis-
tochemical results in muscle [57], making it difﬁcult to judge and
compare the results. Finally, a third study used homoplasmic muta-
tion load and cybrid models [6] instead of primary patient material.
Although there is a possible interference of the nuclear cancer back-
ground here, the increased expression of antioxidant genes nicely
correlates with the lack of oxidative damage. Altogether, all studies
point to increased ROS production, whether or not compensated by
antioxidant defenses. These studies emphasize the importance of
standardization and examining different aspects of oxidative stress
to be able to compare the results of different studies, especially if het-
erogeneous patient populations or different model systems with dif-
ferent adaptive capacities are being used.4.2.3. Patients with mutations in the POLG1 gene
All except one POLG1 cell line showed increased ROS levels. POLG1
cell line 06E0703 has the samemutation as cell line 2862S, while only
the latter showed increased ROS levels (Table 7). This may be related
to the random effect of pol γ on mtDNA stability and point mutations
leading to many, random low level heteroplasmy mutations in con-
trast to the high heteroplasmic CI and tRNA-Leu mutations. As
suggested by the multiple gene expression changes and glutathione
results, the POLG1 cell lines were able to adaptively activate the anti-
oxidant or repair systems associated with increased endogenous ROS
levels [58]. No human cells or tissues with POLG1 mutations have
been evaluated for oxidative stress parameters so far. In POLGmutator
mice with proofreading deﬁcient D268A polymerase resulting in
the random accumulation of mtDNA mutations, no or only mildly in-
creased ROS production and no oxidative damage could be detected
in several tissues (liver, heart, muscle) by two groups [25,26]. Con-
trastingly, a third group examining the same mice, did observe in-
creased oxidative protein damage in the heart which could be
attenuated by overexpression of mitochondrial catalase [59]. Addi-
tionally, in transgenic mice with cardiac-targeted human mutant
Y955C pol γ, affecting the polymerase domain, increased oxidative
DNA damage associated with decreasedmtDNA copy number was ob-
served [27]. In concordance with the latter publications, the current
study implies that ROS levels are increased in most POLG1 patients
and therefore their antioxidant levels and oxidative damage markers
should be followed up to supplement them with antioxidants when
their endogenous system starts failing.4.3. Correlations between different oxidative stress parameters
A consistent correlation was observed between classic antioxidant
genes and the other oxidative stress parameters. ROS levels were in-
versely correlated with CAT expression and protein carbonyl levels
were correlated with GPX1 gene expression. ROS levels have shown
previously to inhibit catalase directly [60], whereas GPX1 was crucial
for protection against protein oxidation in mice [61], both of which
might explain the observed correlations. Therefore, the expression
of these genes might serve as biological biomarkers, although this re-
mains to be conﬁrmed in a larger patient cohort.5. Conclusions
In this study using ﬁbroblasts of patients with different genetically
characterized OXPHOS disease, it was shown that in the majority ROS
was increased and could lead to oxidative damage in different OXPHOS
disorders, although not in every patient-derived ﬁbroblast. This has to
be determined individually. Whether this also applies to more clinically
relevant tissues, like brain and muscle of those patients, is not clear,
but is not unlikely given data from literature involving other tissues
[19,62,63] and mouse studies [27,64] illustrating that ﬁbroblasts are
not the most sensitive system. Therefore, patient-derived ﬁbroblasts
can be used to identify patientswith increased risk for oxidative damage,
whowill most likely beneﬁt from boosting their antioxidant defense and
energy capacity (training), possibly leading to patient-tailored preven-
tion and antioxidant therapy in the future.
Supplementary data to this article can be found online at http://
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